TW200612929A - Novel 2,6-diaminopyridine-3-one derivatives - Google Patents

Novel 2,6-diaminopyridine-3-one derivatives

Info

Publication number
TW200612929A
TW200612929A TW094123936A TW94123936A TW200612929A TW 200612929 A TW200612929 A TW 200612929A TW 094123936 A TW094123936 A TW 094123936A TW 94123936 A TW94123936 A TW 94123936A TW 200612929 A TW200612929 A TW 200612929A
Authority
TW
Taiwan
Prior art keywords
novel
compounds
diaminopyridine
derivatives
treatment
Prior art date
Application number
TW094123936A
Other languages
English (en)
Inventor
David Joseph Bartkovitz
Xin-Jie Chu
Allen John Lovey
Peter Michael Wovkulich
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35385535&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TW200612929(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of TW200612929A publication Critical patent/TW200612929A/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/73—Unsubstituted amino or imino radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4406—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Mobile Radio Communication Systems (AREA)
TW094123936A 2004-07-15 2005-07-14 Novel 2,6-diaminopyridine-3-one derivatives TW200612929A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US58812204P 2004-07-15 2004-07-15

Publications (1)

Publication Number Publication Date
TW200612929A true TW200612929A (en) 2006-05-01

Family

ID=35385535

Family Applications (1)

Application Number Title Priority Date Filing Date
TW094123936A TW200612929A (en) 2004-07-15 2005-07-14 Novel 2,6-diaminopyridine-3-one derivatives

Country Status (16)

Country Link
US (1) US7423051B2 (zh)
EP (1) EP1771420B1 (zh)
JP (1) JP2008505955A (zh)
KR (1) KR100853973B1 (zh)
CN (1) CN1980893B (zh)
AR (1) AR050427A1 (zh)
AT (1) ATE445604T1 (zh)
AU (1) AU2005261899A1 (zh)
BR (1) BRPI0513366A (zh)
CA (1) CA2573604A1 (zh)
DE (1) DE602005017152D1 (zh)
ES (1) ES2330765T3 (zh)
MX (1) MX2007000574A (zh)
RU (1) RU2385866C2 (zh)
TW (1) TW200612929A (zh)
WO (1) WO2006005548A1 (zh)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007137196A2 (en) * 2006-05-19 2007-11-29 Threshold Pharmaceuticals, Inc. Tubulin binding anti cancer compounds and prodrugs thereof
EP1900727A1 (en) * 2006-08-30 2008-03-19 Cellzome Ag Aminopyridine derivatives as kinase inhibitors
US8017607B2 (en) 2009-10-14 2011-09-13 Hoffmann-La Roche Inc. N-substituted-pyrrolidines as inhibitors of MDM2-P-53 interactions
KR20220137002A (ko) * 2019-12-20 2022-10-11 에보포인트 바이오사이언시스 컴퍼니 리미티드 헤테로고리 화합물 및 그의 약제학적 조성물, 제조 방법, 중간체 및 용도
KR20230142504A (ko) * 2021-02-05 2023-10-11 상하이 치루 파마슈티컬 리서치 앤 디벨롭먼트 센터 리미티드 Cdk 억제제
CN113117077B (zh) * 2021-03-04 2022-08-09 西南民族大学 一种用于肿瘤联合治疗的铂基单原子纳米酶及其制备方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004500304A (ja) * 1997-10-27 2004-01-08 アグロン　ファ−マシュ−テイカルズ　インコ−ポレイテッド ４−アミノチアゾ−ル誘導体、その製造法およびサイクリン依存キナ−ゼ抑制剤としての使用法
US6262096B1 (en) * 1997-11-12 2001-07-17 Bristol-Myers Squibb Company Aminothiazole inhibitors of cyclin dependent kinases
AU5108000A (en) * 1999-06-10 2001-01-02 Yamanouchi Pharmaceutical Co., Ltd. Novel nitrogen-contaiing heterocyclic derivatives or salts thereof
YU18502A (sh) 1999-09-15 2004-12-31 Warner-Lambert Company Pteridinoni kao inhibitori kinaza
CA2386955A1 (en) 1999-11-22 2001-05-31 Warner-Lambert Company Quinazolines and their use for inhibiting cyclin-dependent kinase enzymes
WO2001079198A1 (en) 2000-04-18 2001-10-25 Agouron Pharmaceuticals, Inc. Pyrazoles for inhibiting protein kinase
JP2006518368A (ja) 2003-02-21 2006-08-10 ファイザー・インク プロテインキナーゼ阻害剤としてのｎ−ヘテロシクリル置換アミノチアゾール誘導体
CN1905872A (zh) 2003-11-19 2007-01-31 詹森药业有限公司 用于治疗激酶紊乱的氨基取代的吡啶甲酮化合物

Also Published As

Publication number Publication date
MX2007000574A (es) 2007-03-07
EP1771420B1 (en) 2009-10-14
JP2008505955A (ja) 2008-02-28
ES2330765T3 (es) 2009-12-15
CN1980893A (zh) 2007-06-13
KR100853973B1 (ko) 2008-08-25
ATE445604T1 (de) 2009-10-15
BRPI0513366A (pt) 2008-05-06
RU2385866C2 (ru) 2010-04-10
US20060014708A1 (en) 2006-01-19
AR050427A1 (es) 2006-10-25
CA2573604A1 (en) 2006-01-19
EP1771420A1 (en) 2007-04-11
RU2007105558A (ru) 2008-08-20
WO2006005548A1 (en) 2006-01-19
KR20070028539A (ko) 2007-03-12
DE602005017152D1 (de) 2009-11-26
CN1980893B (zh) 2011-01-19
US7423051B2 (en) 2008-09-09
AU2005261899A1 (en) 2006-01-19

Similar Documents

Publication Publication Date Title
TNSN05188A1 (en) 4-aminopyrimidine-5-one
WO2002057261A3 (en) Diaminothiazoles and their use as inhibitors of cyclin-dependent kinase
BRPI0511975A (pt) pirazolopirimidinas
TW200407326A (en) Pyrimido compounds having antiproliferative activity
WO2006081230A3 (en) 3-(indazol-5-yl)-(1,2, 4) triazine derivatives and related compounds as protein kinase inhibitors for the treatment of cancer
EA025871B9 (ru) Ингибиторы mek и способы их применения
TW200724543A (en) Heterocyclic compounds and their uses as therapeutic agents
ATE453636T1 (de) Substituierte 2,3-dihydro-1h-isoindol-1-one derivate und anwendungsverfahren
MXPA06009475A (es) Derivados de quinazolina y usos terapeuticos de los mismos.
TNSN08020A1 (en) 1,4-dihydropyridine-fused heterocycles, process for preparing the same, use and compositions containing them
PL1809288T3 (pl) Zastosowanie pochodnych 1,4-bis-(3-aminoalkilo)piperazyny do leczenia chorób neurodegeneracyjnych
TW200612929A (en) Novel 2,6-diaminopyridine-3-one derivatives
NO20061318L (no) 6-[-(substituerte) fenyl] Triazolopyrimidiner somanticancer midler
DE60215682D1 (de) AZAOXOINDOL DERIVATE ALS Trk PROTEIN KINASE HEMMSTOFFE ZUR BEHANDLUNG VON KREBS UND CHRONISCHEM SCHMERZ
MX2010003269A (es) Derivados de pirrolotriazina utiles para tratar cancer a traves de la inhibicion de la aurora quinasa.
MX2008002060A (es) Nuevas amidas de acido 4-amino-tieno[3,2-c]piridin-7-carboxilico.
WO2005103034A8 (en) Novel piperidine substituted diaminothiazoles
PT1606288E (pt) Derivados de benzenossulfonamida, processo para a sua preparação e a sua utilização para tratamento da dor
BRPI0511826A (pt) derivados de 2,4-diaminotiazol-5-ona
WO2006066183A3 (en) Novel saframycin analogs as therapeutic agents
BRPI0815334A2 (pt) derivados de pirazolo[3,4-d]-piramidina como agentes antiproliferativos
TW200730177A (en) 4 anilino-3-quinolinecarbonitriles for the treatment of cancer
DE602004009097D1 (de) 1.3.4-triaza-phenalen- und 1,3,4,6-tetraazaphenalen-derivative
HK1082727A1 (en) 2" oxo-voruscharin and derivatives thereof